CGEM

Cullinan Therapeutics Inc

Apr 09 • 02:36PM ET

15.07

+0.11 0.71 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD INCY JAZZ NVAX KURA EXEL BPMC KPTI ESPR ONCY

| Held by: VTI XBI IWM VXF IWN IBB VTWO SCHA DFAS DFMC

Index	RUT	P/E	-	EPS (ttm)	-3.72	Insider Own	26.68%	Shs Outstand	60.24M	Perf Week	8.07%
Market Cap	911.86M	Forward P/E	-	EPS next Y	-2.81	Insider Trans	12.25%	Shs Float	44.38M	Perf Month	1.04%
Enterprise Value	536.64M	PEG	-	EPS next Q	-0.83	Inst Own	80.88%	Short Float	18.85%	Perf Quarter	37.71%
Income	-219.88M	P/S	-	EPS this Y	10.97%	Inst Trans	2.24%	Short Ratio	10.61	Perf Half Y	155.78%
Sales	0.00M	P/B	2.22	EPS next Y	6.14%	ROA	-41.04%	Short Interest	8.36M	Perf YTD	45.56%
Book/sh	6.78	P/C	2.41	EPS next 5Y	6.95%	ROE	-44.02%	52W High	16.74 -10.00%	Perf Year	93.40%
Cash/sh	6.24	P/FCF	-	EPS past 3/5Y	- -25.62%	ROIC	-53.55%	52W Low	5.68 165.24%	Perf 3Y	49.91%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.23% 6.87%	Perf 5Y	-53.36%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-18.75%	Oper. Margin	-	ATR (14)	0.94	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.25	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	60.04	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.25	EPS Q/Q	-5.31%	SMA20	8.88%	Beta	-0.01	Target Price	32.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	10.22%	Rel Volume	0.39	Prev Close	14.96
Employees	109	LT Debt/Eq	0.00	Earnings	Mar 10 BMO	SMA200	53.97%	Avg Volume	788.52K	Price	15.07
IPO	Jan 08, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.87% -100.00%	Trades		Volume	244,814	Change	0.71%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-17-26	Initiated	Citigroup	Buy	$33
Feb-02-26	Initiated	Guggenheim	Buy	$30
Aug-21-25	Resumed	H.C. Wainwright	Buy	$24
Jun-11-25	Resumed	Stifel	Buy	$22
Oct-24-24	Initiated	UBS	Buy	$30
May-01-24	Initiated	Stifel	Buy	$40
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform	$30
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy	$20
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40
Feb-02-21	Initiated	SVB Leerink	Outperform	$52
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight	$38
Feb-02-21	Initiated	Evercore ISI	Outperform	$55
Feb-01-21	Initiated	H.C. Wainwright	Buy	$47

Show Previous Ratings

Mar-10-26 07:23AM	Cullinan Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-08-26 12:03AM	Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference (MarketBeat)
Feb-24-26 07:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-19-26 08:12PM	Cullinan Therapeutics Touts 2026 Defining Year as T-Cell Engager, Zipalertinib Catalysts Near (MarketBeat) +11.58%
07:17AM	Loading…
07:17AM	TheStreet Pro Analysts Say, Its a Stock Pickers Market Here Are 4 to Consider (TipRanks)
Feb-18-26 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-13-26 02:09AM	Cullinan Therapeutics Tees Up Catalyst-Heavy 2026 With Q2 CLN-978 Data and AML Fast Track Momentum (MarketBeat)
Feb-05-26 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-28-26 09:40AM	Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? (Zacks)
Jan-23-26 08:55AM	Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength (Zacks)
Jan-09-26 07:15AM	Cullinan Therapeutics provides corporate update, anticipated 2026 milestones (TipRanks)
Jan-08-26 07:00AM	Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones (GlobeNewswire)
Dec-15-25 11:10PM	Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates (Insider Monkey) -9.23% -5.55%
Dec-08-25 10:31AM	Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting (GlobeNewswire) +17.47%
07:00AM	Loading…
Dec-01-25 07:00AM	Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire) -5.45%
Nov-10-25 07:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting (GlobeNewswire)
Nov-06-25 07:38AM	Cullinan Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 09:11AM	Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting (GlobeNewswire) -9.82%
Oct-25-25 11:01AM	Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025 (GlobeNewswire)
Sep-23-25 10:23AM	BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy? (Zacks)
Sep-12-25 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum (GlobeNewswire)
Aug-21-25 04:05PM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.78%
Aug-07-25 07:15AM	Cullinan Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -10.79%
07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 11:40PM	Cullinan Therapeutics to Present Updated Zipalertinib Data at IASLC 2025 World Conference on Lung Cancer (Insider Monkey)
Jul-22-25 07:00AM	Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer (PR Newswire) +7.85%
Jul-14-25 08:30AM	Disc Medicine Appoints Nadim Ahmed to its Board of Directors (GlobeNewswire)
Jun-05-25 07:31AM	Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal (BioPharma Dive)
04:02PM	Loading…
Jun-04-25 04:02PM	Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases (GlobeNewswire)
Jun-01-25 08:21AM	Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology (PR Newswire)
May-29-25 07:00AM	Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference (GlobeNewswire) +10.71%
May-22-25 05:15PM	Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 (GlobeNewswire)
May-08-25 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 09:55AM	Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know (Zacks)
Apr-29-25 07:00AM	Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sj gren's Disease in the United States (GlobeNewswire)
Apr-23-25 10:14AM	Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 (GlobeNewswire)
Apr-16-25 07:00AM	Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis (GlobeNewswire)
Apr-08-25 10:42AM	Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data (Seeking Alpha)
Feb-27-25 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-24-25 07:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-25 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-28-25 07:00PM	Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy (PR Newswire) +7.66%
Nov-14-24 10:01AM	Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 (GlobeNewswire)
Nov-07-24 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire) -5.46%
Nov-05-24 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-04-24 07:00AM	Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 (GlobeNewswire)
Oct-16-24 07:00AM	Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus (GlobeNewswire) +8.44%
Sep-17-24 07:00AM	Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus (GlobeNewswire)
Sep-16-24 07:00AM	Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus (GlobeNewswire) -5.68%
Sep-14-24 04:15AM	Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-03-24 06:26AM	Cullinan Therapeutics announces success for zipalertinib as combo therapy (Clinical Trials Arena)
Jun-01-24 07:00AM	Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib (GlobeNewswire)
May-24-24 08:00AM	Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire) +6.53%
May-23-24 05:04PM	Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 (GlobeNewswire)
May-16-24 12:03PM	HC Wainwright Adjusts Price Target on Cullinan Oncology to $28 From $29, Maintains Buy Rating (MT Newswires) -10.89%
May-15-24 10:54PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 03:09AM	Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ... (GuruFocus.com)
May-01-24 07:05AM	Stifel Initiates Cullinan Oncology With Buy Rating, $40 Price Target (MT Newswires)
Apr-29-24 07:00AM	Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer (GlobeNewswire) +7.19%
Apr-24-24 04:29PM	Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? (Benzinga) +13.32%
10:09AM	Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024 (GlobeNewswire)
Apr-16-24 03:32PM	Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity (Benzinga)
07:00AM	Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases (GlobeNewswire)
06:59AM	Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement (GlobeNewswire)
04:48AM	Cullinan changes name, pivots to autoimmune disease (BioPharma Dive)
Mar-16-24 05:31AM	Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
Mar-14-24 12:53PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-01-24 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Feb-27-24 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-02-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-30-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-24-24 07:02PM	Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares (GuruFocus.com)
Dec-18-23 04:53PM	Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.80%
Dec-14-23 04:30PM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines (GlobeNewswire)
Nov-08-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 12:01PM	Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023 (GlobeNewswire) +5.53%
Oct-30-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-06-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 07:00AM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (GlobeNewswire)
Aug-03-23 04:15PM	REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations (PR Newswire)
Jul-31-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-09-23 04:07PM	Why Shares of Cullinan Oncology Jumped This Week (Motley Fool)
May-25-23 05:00PM	Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023 (GlobeNewswire) +5.13%
May-11-23 04:01PM	Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-26-23 10:08AM	Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023 (GlobeNewswire)
Apr-20-23 07:00AM	Cullinan Oncology to Participate in Stifels 2023 Targeted Oncology Days (GlobeNewswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-27-23 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines (GlobeNewswire)
Mar-14-23 04:35PM	Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-09-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 08:00AM	Cullinan Oncology to Participate in Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-13-23 07:00PM	Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed (GlobeNewswire)

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Michaelson Jennifer	Chief Scientific Officer	Mar 05 '26	Option Exercise	4.30	4,000	17,200	178,844	Mar 09 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Mar 05 '26	Sale	15.68	8,000	125,440	170,844	Mar 09 05:00 PM
JENNIFER MICHAELSON	Officer	Mar 05 '26	Proposed Sale	16.30	8,000	130,400		Mar 05 04:31 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 25 '26	Sale	14.14	1,780	25,169	174,844	Feb 26 05:05 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 24 '26	Sale	14.47	3,601	52,106	176,624	Feb 25 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 23 '26	Sale	13.99	1,752	24,510	180,225	Feb 25 05:00 PM
AHMED NADIM	President and CEO	Feb 24 '26	Sale	14.47	13,515	195,562	390,803	Feb 25 05:00 PM
Jones Jeffrey Alan	Chief Medical Officer	Feb 24 '26	Sale	14.47	4,582	66,302	159,968	Feb 25 05:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Feb 24 '26	Sale	14.47	3,601	52,106	128,089	Feb 25 05:00 PM
JENNIFER MICHAELSON	Officer	Feb 25 '26	Proposed Sale	14.27	1,780	25,401		Feb 25 04:33 PM
Jones Jeffrey Alan	Chief Medical Officer	Feb 20 '26	Sale	13.62	4,982	67,855	164,550	Feb 23 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 20 '26	Option Exercise	4.30	8,000	34,400	189,977	Feb 23 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 20 '26	Sale	14.08	11,742	165,366	181,977	Feb 23 05:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Feb 20 '26	Sale	13.62	3,742	50,966	131,690	Feb 23 05:00 PM
AHMED NADIM	President and CEO	Feb 20 '26	Sale	13.62	16,381	223,109	404,318	Feb 23 05:00 PM
Fenton Mary Kay	Chief Financial Officer	Feb 20 '26	Sale	13.62	4,398	59,901	126,380	Feb 23 05:00 PM
JENNIFER MICHAELSON	Officer	Feb 23 '26	Proposed Sale	13.65	1,752	23,915		Feb 23 04:31 PM
JENNIFER MICHAELSON	Officer	Feb 20 '26	Proposed Sale	13.88	8,000	111,040		Feb 20 04:27 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 12 '26	Sale	12.03	416	5,004	128,219	Feb 13 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Jan 22 '26	Sale	12.30	4,000	49,200	128,635	Jan 23 05:00 PM
JENNIFER MICHAELSON	Officer	Jan 22 '26	Proposed Sale	11.60	4,000	46,400		Jan 22 04:33 PM
AHMED NADIM	President and CEO	Dec 23 '25	Sale	10.01	9,922	99,319	420,699	Dec 29 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 19 '25	Sale	10.01	1,345	13,463	132,635	Dec 22 05:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Dec 18 '25	Sale	9.67	3,480	33,652	135,432	Dec 19 05:00 PM
Jones Jeffrey Alan	Chief Medical Officer	Dec 18 '25	Sale	9.67	4,632	44,791	169,532	Dec 19 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 18 '25	Sale	9.67	2,898	28,024	133,980	Dec 19 05:00 PM
JENNIFER MICHAELSON	Officer	Dec 19 '25	Proposed Sale	9.98	1,345	13,423		Dec 19 04:23 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 12 '25	Sale	12.38	2,148	26,592	137,873	Dec 16 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 15 '25	Sale	11.90	995	11,840	136,878	Dec 16 05:00 PM
JENNIFER MICHAELSON	Officer	Dec 15 '25	Proposed Sale	11.92	995	11,860		Dec 15 04:16 PM
Michaelson Jennifer	Chief Scientific Officer	Nov 24 '25	Sale	12.30	4,000	49,200	138,004	Nov 25 05:00 PM
JENNIFER MICHAELSON	Officer	Nov 24 '25	Proposed Sale	9.47	4,000	37,880		Nov 24 04:28 PM
Lynx1 Capital Management LP	10% Owner	Oct 28 '25	Buy	8.40	165,667	1,391,686	8,963,500	Oct 30 05:13 PM
Lynx1 Capital Management LP	10% Owner	Oct 16 '25	Buy	8.86	150,000	1,328,250	8,765,616	Oct 21 07:00 PM
Lynx1 Capital Management LP	10% Owner	Oct 15 '25	Buy	7.94	51,500	409,049	8,615,616	Oct 21 07:00 PM
Lynx1 Capital Management LP	10% Owner	Oct 17 '25	Buy	7.84	32,217	252,565	8,797,833	Oct 21 07:00 PM
Lynx1 Capital Management LP	10% Owner	Oct 14 '25	Buy	7.59	15,032	114,048	8,564,116	Oct 21 07:00 PM
Lynx1 Capital Management LP	10% Owner	Oct 09 '25	Buy	6.70	626,043	4,191,859	8,271,786	Oct 10 06:58 PM
Lynx1 Capital Management LP	10% Owner	Oct 08 '25	Buy	6.46	556,300	3,593,698	7,645,743	Oct 10 06:58 PM
Lynx1 Capital Management LP	10% Owner	Oct 10 '25	Buy	7.36	277,298	2,041,385	8,549,084	Oct 10 06:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGEM

Cullinan Therapeutics Inc

Upgrade your Finviz experience